Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope

• Published in: Scientific reports Vol. 13; no. 1; p. 16801
• Main Authors: Mashhadi Abolghasem Shirazi, Maryam, Sadat, Seyed Mehdi, Haghighat, Setareh, Roohvand, Farzin, Arashkia, Arash
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group 05.10.2023; Nature Publishing Group UK; Nature Portfolio
• Subjects: Adjuvants; Agonists; Capsid protein; E coli; Epitopes; Human papillomavirus; Immune response; Immunization; Immunogenicity; Lymphocytes T; Tetanus; TLR4 protein; TLR7 protein; Toll-like receptors; Vaccines
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-43965-3

To relieve the limitations of the human papillomavirus (HPV) vaccines based on L1 capsid protein, vaccine formulations based on RG1 epitope of HPV L2 using various built-in adjuvants are under study. Herein, we describe design and construction of a rejoined peptide (RP) harboring HPV16 RG1 epitope fused to TLR4/5 agonists and a tetanus toxoid epitope, which were linked by the (GGGS)3 linker in tandem. In silico analyses indicated the proper physicochemical, immunogenic and safety profile of the RP. Docking analyses on predicted 3D model suggested the effective interaction of TLR4/5 agonists within RP with their corresponding TLRs. Expressing the 1206 bp RP-coding DNA in E. coli produced a 46 kDa protein, and immunization of mice by natively-purified RP in different adjuvant formulations indicated the crucial role of the built-in adjuvants for induction of anti-RG1 responses that could be further enhanced by combination of TLR7 agonist/alum adjuvants. While the TLR4/5 agonists contributed in the elicitation of the Th2-polarized immune responses, combination with TLR7 agonist changed the polarization to the balanced Th1/Th2 immune responses. Indeed, RP + TLR7 agonist/alum adjuvants induced the strongest immune responses that could efficiently neutralize the HPV pseudoviruses, and thus might be a promising formulation for an inexpensive and cross-reactive HPV vaccine.